|
US4898278A
(en)
|
1986-12-05 |
1990-02-06 |
Nalge Company |
Storage container
|
|
JPH10113117A
(ja)
|
1996-10-11 |
1998-05-06 |
Tomoji Tanaka |
保冷箱
|
|
CA2289702C
(en)
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
|
US20030083272A1
(en)
|
1997-09-19 |
2003-05-01 |
Lahive & Cockfield, Llp |
Sense mrna therapy
|
|
AU2998800A
(en)
|
1999-03-24 |
2000-10-09 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
N-acylphosphoramidites and their use in oligonucleotide synthesis
|
|
US6381981B1
(en)
|
2001-05-02 |
2002-05-07 |
Advanced Tissue Sciences, Inc. |
Container for shipping and storing frozen products
|
|
ATE490267T1
(de)
|
2001-06-05 |
2010-12-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
|
|
US20030082357A1
(en)
|
2001-09-05 |
2003-05-01 |
Cem Gokay |
Multi-layer core for vacuum insulation panel and insulated container including vacuum insulation panel
|
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
|
AU2003245729A1
(en)
|
2002-06-27 |
2004-01-19 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating a cytotoxic t lymphocyte immune response
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
WO2004071493A1
(en)
*
|
2003-02-17 |
2004-08-26 |
Peter Burkhard |
Peptidic nanoparticles as drug delivery and antigen display systems
|
|
US7897744B2
(en)
|
2003-04-28 |
2011-03-01 |
The Public Health Agency Of Canada |
SARS virus nucleotide and amino acid sequences and uses thereof
|
|
CN1820020B
(zh)
|
2003-05-06 |
2010-04-28 |
技术持有有限公司 |
Sars-冠状病毒病毒样颗粒以及应用方法
|
|
JP2007527631A
(ja)
|
2003-06-10 |
2007-09-27 |
ノキア コーポレイション |
自律送信とスケジュール送信間での移動局の切替えを行う方法及び装置
|
|
WO2005005596A2
(en)
|
2003-06-18 |
2005-01-20 |
Chinese National Human Genome Center At Shanghai |
Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
|
|
WO2005012337A2
(en)
|
2003-07-15 |
2005-02-10 |
Crucell Holland B.V. |
Antigenic peptides of sars coronavirus and uses thereof
|
|
CA2531684C
(en)
|
2003-07-22 |
2014-03-11 |
Crucell Holland B.V. |
Binding molecules against sars-coronavirus and uses thereof
|
|
US20070270361A1
(en)
|
2003-08-04 |
2007-11-22 |
Shan Lu |
Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
|
|
TW200515917A
(en)
*
|
2003-09-15 |
2005-05-16 |
Us Government |
Methods and compositions for the generation of a protective immune response against SARS-COV
|
|
US7129042B2
(en)
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
|
EP2361974A1
(fr)
|
2003-12-02 |
2011-08-31 |
Institut Pasteur |
Utilisation des proteines et des peptides codés par le genome d'une nouvelle souche de coronavirus associé au SRAS
|
|
US20050178142A1
(en)
|
2004-02-17 |
2005-08-18 |
Perry Ralph J. |
96 hour duration insulated cryo-pack for maintaining -40 degree fahrenheit
|
|
CA2568838A1
(en)
|
2004-06-04 |
2005-12-15 |
Institut Pasteur |
Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
|
|
US7870748B2
(en)
|
2005-02-25 |
2011-01-18 |
Byrne Kathleen H |
Method for controlled rate freezing and long term cryogenic storage
|
|
US20070124833A1
(en)
|
2005-05-10 |
2007-05-31 |
Abad Mark S |
Genes and uses for plant improvement
|
|
US9006487B2
(en)
|
2005-06-15 |
2015-04-14 |
Massachusetts Institute Of Technology |
Amine-containing lipids and uses thereof
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
EP2049665A2
(en)
|
2006-07-28 |
2009-04-22 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
|
US8865398B2
(en)
|
2006-09-01 |
2014-10-21 |
Abbott Laboratories |
Combination hepatitis C virus antigen and antibody detection method
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
WO2008157688A2
(en)
|
2007-06-19 |
2008-12-24 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
PL215513B1
(pl)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
|
|
AU2015210364B2
(en)
|
2008-10-09 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
GB0818663D0
(en)
*
|
2008-10-10 |
2008-11-19 |
Ark Therapeutics Ltd |
Gene regulation and its use in therapy
|
|
JP5813513B2
(ja)
|
2008-12-09 |
2015-11-17 |
ノババックス，インコーポレイテッド |
修飾ｒｓｖｆタンパク質及びその使用方法
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
US20110300205A1
(en)
|
2009-07-06 |
2011-12-08 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
|
HUE042177T2
(hu)
|
2009-12-01 |
2019-06-28 |
Translate Bio Inc |
Szteroidszármazék mRNS szállítására humán genetikai betegségekben
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
AU2015210336B2
(en)
|
2010-08-17 |
2017-05-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
|
RS63890B1
(sr)
*
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012158736A1
(en)
|
2011-05-17 |
2012-11-22 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
PL3586861T3
(pl)
|
2011-06-08 |
2022-05-23 |
Translate Bio, Inc. |
Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
US20140378538A1
(en)
|
2011-12-14 |
2014-12-25 |
Moderma Therapeutics, Inc. |
Methods of responding to a biothreat
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
JP2015510495A
(ja)
|
2011-12-21 |
2015-04-09 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
器官または器官移植片の生存可能性または寿命を延長する方法
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
EP3260541B1
(en)
|
2012-03-27 |
2019-05-15 |
CureVac AG |
Artificial nucleic acid molecules for improved protein or peptide expression
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US20150050354A1
(en)
*
|
2012-04-02 |
2015-02-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the treatment of otic diseases and conditions
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US9687448B2
(en)
|
2012-12-07 |
2017-06-27 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid lipid particle formulations
|
|
WO2014093574A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
EP2958588B1
(en)
|
2013-02-22 |
2017-08-23 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
RU2718988C2
(ru)
|
2013-02-22 |
2020-04-15 |
Куревак Аг |
Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
|
|
US20160022840A1
(en)
|
2013-03-09 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
PL3467108T3
(pl)
|
2013-03-14 |
2024-09-30 |
Translate Bio, Inc. |
Sposoby oczyszczania informacyjnego rna
|
|
CN105051213A
(zh)
|
2013-03-14 |
2015-11-11 |
夏尔人类遗传性治疗公司 |
信使rna加帽效率的定量评估
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
WO2014144711A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
CA2906732C
(en)
|
2013-03-15 |
2023-08-08 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
EP3036330B1
(en)
|
2013-08-21 |
2018-09-12 |
CureVac AG |
Method for increasing expression of rna-encoded proteins
|
|
SG11201510747RA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
EP3062798B1
(en)
|
2013-11-01 |
2020-05-06 |
CureVac AG |
Modified rna with decreased immunostimulatory properties
|
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
|
WO2015080973A1
(en)
*
|
2013-11-26 |
2015-06-04 |
Baylor College Of Medicine |
A novel sars immunogenic composition
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
EP3090060B2
(en)
|
2013-12-30 |
2025-05-21 |
CureVac Manufacturing GmbH |
Methods for rna analysis
|
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
PT3134506T
(pt)
|
2014-04-25 |
2019-10-31 |
Translate Bio Inc |
Métodos de purificação de rna mensageiro
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
WO2016005004A1
(en)
*
|
2014-07-11 |
2016-01-14 |
Biontech Rna Pharmaceuticals Gmbh |
Stabilization of poly(a) sequence encoding dna sequences
|
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ポリヌクレオチドの末端修飾
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
WO2016077123A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Multiparametric nucleic acid optimization
|
|
DE202015010000U1
(de)
|
2014-12-12 |
2023-07-03 |
CureVac SE |
Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
|
|
US20180000953A1
(en)
|
2015-01-21 |
2018-01-04 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
SG11201707663SA
(en)
|
2015-04-17 |
2017-11-29 |
Curevac Ag |
Lyophilization of rna
|
|
US20180303925A1
(en)
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
|
DK3294885T3
(da)
|
2015-05-08 |
2020-08-10 |
Curevac Real Estate Gmbh |
Fremgangsmåde til at fremstille rna
|
|
EP3297682B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
PL4108769T3
(pl)
|
2015-05-29 |
2024-02-05 |
CureVac Manufacturing GmbH |
Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
WO2017025447A1
(en)
|
2015-08-10 |
2017-02-16 |
Curevac Ag |
Method of increasing the replication of a circular dna molecule
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
JP7078812B2
(ja)
|
2015-08-28 |
2022-06-01 |
バイオンテック・エスイー |
Ｒｎａの免疫原性を低減するための方法
|
|
EP4286012A3
(en)
|
2015-09-17 |
2024-05-29 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2017049286A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
|
PL3350333T3
(pl)
|
2015-09-17 |
2022-03-07 |
Modernatx, Inc. |
Polinukleotydy zawierające region stabilizujący ogon
|
|
ES2964690T3
(es)
|
2015-09-21 |
2024-04-09 |
Trilink Biotechnologies Llc |
Método para sintetizar ARN con caperuza 5'
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017059902A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
|
|
WO2017066781A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
AU2016342049B2
(en)
|
2015-10-22 |
2023-05-18 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
MX2018004917A
(es)
|
2015-10-22 |
2019-04-01 |
Modernatx Inc |
Vacuna de virus sincitial respiratorio.
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
CA3002912A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
WO2017070620A2
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11389546B2
(en)
|
2015-12-09 |
2022-07-19 |
Modernatx, Inc. |
Heterologous UTR sequences for enhanced mRNA expression
|
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
|
MA43568A
(fr)
|
2015-12-17 |
2018-11-14 |
Modernatx Inc |
Polynucléotides codant pour la méthylmalonyl-coa mutase
|
|
HUE057877T2
(hu)
|
2015-12-22 |
2022-06-28 |
Modernatx Inc |
Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
GB2546257A
(en)
|
2016-01-08 |
2017-07-19 |
The Wool Packaging Company Ltd |
Temperature controlled packaging and transportation method
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
WO2017162266A1
(en)
*
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
US20190167811A1
(en)
|
2016-04-13 |
2019-06-06 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
WO2017201317A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
AU2017266932B2
(en)
|
2016-05-18 |
2023-04-20 |
Modernatx, Inc. |
Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
|
|
WO2017201347A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
MA45032A
(fr)
|
2016-05-18 |
2019-03-27 |
Fundacion Para La Investig Medica Aplicada |
Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
|
|
KR20230074598A
(ko)
|
2016-05-18 |
2023-05-30 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
|
|
WO2017201352A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
MA45036A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
|
|
WO2017201348A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
GB201611050D0
(en)
|
2016-06-24 |
2016-08-10 |
Softbox Systems Ltd |
A passive temperature control system for transport and storage containers
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
US10487105B2
(en)
*
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
EP4599847A3
(en)
|
2016-10-25 |
2025-11-12 |
Trustees of Dartmouth College |
Prefusion coronavirus spike proteins and their use
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
ES3063077T3
(en)
*
|
2016-10-26 |
2026-04-15 |
Acuitas Therapeutics Inc |
Lipid nanoparticle formulations
|
|
EP3532613A4
(en)
|
2016-10-26 |
2020-05-06 |
ModernaTX, Inc. |
METHOD AND COMPOSITIONS FOR RNA MAPPING
|
|
BR112019008481A2
(pt)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
|
EP3558356A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Mers coronavirus vaccine
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
WO2018144778A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Polynucleotide secondary structure
|
|
JP2020514321A
(ja)
|
2017-02-01 |
2020-05-21 |
モデルナティーエックス， インコーポレイテッド |
活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
|
|
EP3576751A4
(en)
|
2017-02-01 |
2021-08-04 |
ModernaTX, Inc. |
RNA ANTI-CANCER VACCINES
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
US20200368162A1
(en)
|
2017-02-24 |
2020-11-26 |
Modernatx, Inc. |
Nucleic Acid-Based Therapy of Muscular Dystrophies
|
|
TW202428301A
(zh)
*
|
2017-02-28 |
2024-07-16 |
法商賽諾菲公司 |
治療性rna
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
US11969506B2
(en)
|
2017-03-15 |
2024-04-30 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
SMT202300097T1
(it)
|
2017-03-15 |
2023-05-12 |
Modernatx Inc |
Composto e composizioni per il rilascio intracellulare di agenti terapeutici
|
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
WO2018188730A1
(en)
*
|
2017-04-11 |
2018-10-18 |
Biontech Rna Pharmaceuticals Gmbh |
Rna for treatment of autoimmune diseases
|
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
|
WO2018213789A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Modified messenger rna comprising functional rna elements
|
|
CN107033250B
(zh)
|
2017-05-23 |
2020-01-21 |
山东省农业科学院奶牛研究中心 |
牛冠状病毒重组多表位抗原及其应用
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
WO2019035998A1
(en)
|
2017-08-17 |
2019-02-21 |
Modernatx, Inc. |
SYSTEMS WITH CONTROL AND REGULATION OF FLUID PATH
|
|
WO2019036683A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
ANALYTICAL METHODS BY HPLC
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
ES2983060T3
(es)
*
|
2017-08-18 |
2024-10-21 |
Modernatx Inc |
Variantes de ARN polimerasa
|
|
MA50751A
(fr)
|
2017-08-18 |
2020-06-24 |
Modernatx Inc |
Vaccins à base d'arnm efficaces
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
WO2019092002A1
(en)
|
2017-11-07 |
2019-05-16 |
Valneva Se |
Pharmaceutical compositions for treatment or prevention of viral infections
|
|
GB201718660D0
(en)
|
2017-11-10 |
2017-12-27 |
Ucl Business Plc |
Improved liposome for mRNA delivery to cells
|
|
EP3713601A4
(en)
|
2017-11-21 |
2022-03-09 |
Modernatx, Inc. |
VACCINES AGAINST EPSTEIN-BARR VIRUS
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
JP2021512090A
(ja)
|
2018-01-30 |
2021-05-13 |
モデルナティーエックス， インコーポレイテッド |
免疫細胞に薬剤を送達するための組成物及び方法
|
|
JP2021521855A
(ja)
|
2018-04-27 |
2021-08-30 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達
|
|
CA3101484A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
CN113365639A
(zh)
|
2018-06-27 |
2021-09-07 |
摩登纳特斯有限公司 |
个性化癌症疫苗表位选择
|
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
|
WO2020056370A1
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CN113271926A
(zh)
|
2018-09-20 |
2021-08-17 |
摩登纳特斯有限公司 |
脂质纳米颗粒的制备及其施用方法
|
|
WO2020072605A1
(en)
|
2018-10-02 |
2020-04-09 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
KR102076917B1
(ko)
*
|
2018-10-25 |
2020-02-13 |
연세대학교 산학협력단 |
자가조립 나노 입자를 제조하기 위한 유전자 재조합 발현 벡터 시스템 및 이를 이용하는 방법
|
|
CA3118947A1
(en)
|
2018-11-07 |
2020-05-14 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
CN111200358B
(zh)
|
2018-11-19 |
2021-09-03 |
广东美的白色家电技术创新中心有限公司 |
抑制冷媒散热器的电磁干扰的系统及家用电器
|
|
TW202515617A
(zh)
|
2019-01-14 |
2025-04-16 |
美商建南德克公司 |
用於癌症療法之rna分子
|
|
JP7635131B2
(ja)
|
2019-01-31 |
2025-02-25 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の調製方法
|
|
CN113795579A
(zh)
|
2019-02-20 |
2021-12-14 |
摩登纳特斯有限公司 |
用于共转录加帽的rna聚合酶变体
|
|
CA3132975A1
(en)
|
2019-03-11 |
2020-09-17 |
Modernatx, Inc. |
Fed-batch in vitro transcription process
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
CN114207134B
(zh)
*
|
2019-03-25 |
2024-11-15 |
俄亥俄州国家创新基金会 |
工程化的mRNA序列及其用途
|
|
AU2020283030A1
(en)
|
2019-05-31 |
2021-12-23 |
Modernatx, Inc. |
Expanded T cell assay
|
|
WO2020263985A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
TWI817018B
(zh)
*
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
CN110378000B
(zh)
|
2019-07-11 |
2020-11-24 |
上海理工大学 |
基于强度场的结构静强度设计方法
|
|
CN114269918A
(zh)
|
2019-08-14 |
2022-04-01 |
摩登纳特斯有限公司 |
用于纯化体外转录的下游产物的方法
|
|
US20230097090A1
(en)
|
2019-08-14 |
2023-03-30 |
Acuitas Therapeutics, Inc. |
Improved lipid nanoparticles for delivery of nucleic acids
|
|
CA3154082A1
(en)
|
2019-09-11 |
2021-03-18 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
JP2022548143A
(ja)
|
2019-09-16 |
2022-11-16 |
アールト・ユニバーシティ・ファウンデイション・エスアール |
バイオ・オイルおよび／または水に基づく均質な繊維製品ならびにその製造方法
|
|
US20220349006A1
(en)
|
2019-09-19 |
2022-11-03 |
Moderna TX, Inc. |
Cap guides and methods of use thereof for rna mapping
|
|
GB201915905D0
(en)
|
2019-11-01 |
2019-12-18 |
Spybiotech Ltd |
Viruses with modified capsid proteins
|
|
WO2021138447A1
(en)
|
2019-12-31 |
2021-07-08 |
Elixirgen Therapeutics, Inc. |
Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
|
|
EP4088281A4
(en)
|
2020-01-10 |
2024-02-21 |
ModernaTX, Inc. |
VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
|
|
WO2021147025A1
(en)
|
2020-01-22 |
2021-07-29 |
The University Of Hong Kong-Shenzhen Hospital |
Anti 2019-ncov vaccine
|
|
CA3165371A1
(en)
|
2020-01-27 |
2021-08-05 |
Gale Smith |
Coronavirus vaccine formulations
|
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
|
JP2023511633A
(ja)
*
|
2020-01-28 |
2023-03-20 |
モデルナティエックス インコーポレイテッド |
コロナウイルスｒｎａワクチン
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
CN115103682A
(zh)
|
2020-01-30 |
2022-09-23 |
摩登纳特斯有限公司 |
呼吸道病毒免疫组合物
|
|
TW202204380A
(zh)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
|
|
WO2021155760A1
(zh)
|
2020-02-03 |
2021-08-12 |
康希诺生物股份公司 |
用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
MX2022009460A
(es)
*
|
2020-02-04 |
2022-12-16 |
Curevac Ag |
Vacuna contra el coronavirus.
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
FI4101864T3
(fi)
|
2020-02-05 |
2025-12-04 |
Shanxi Jinbo Bio Pharmaceutical Co Ltd |
Polypeptidi ja sen valmistusmenetelmä ja sen käyttö
|
|
JP7438604B2
(ja)
*
|
2020-02-07 |
2024-02-27 |
モデルナティエックス インコーポレイテッド |
ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
|
|
CN115297892A
(zh)
|
2020-02-07 |
2022-11-04 |
达冕生物有限公司 |
抗新型冠状病毒感染的mRNA疫苗的组合物和方法
|
|
EP4050035A4
(en)
|
2020-02-10 |
2022-12-28 |
Institute of Microbiology of Chinese Academy of Science |
Beta-coronavirus antigen, preparation method therefor and use thereof
|
|
MX2022009836A
(es)
*
|
2020-02-11 |
2022-11-30 |
Us Health |
Vacuna para sars-cov-2.
|
|
WO2021163371A1
(en)
|
2020-02-12 |
2021-08-19 |
La Jolla Institute For Immunology |
Coronavirus t cell epitopes and uses thereof
|
|
CN113186203B
(zh)
|
2020-02-13 |
2022-12-30 |
斯微(上海)生物科技股份有限公司 |
治疗或者预防冠状病毒病的疫苗试剂
|
|
WO2021160346A1
(en)
|
2020-02-13 |
2021-08-19 |
Institut Pasteur |
Nucleic acid vaccine against the sars-cov-2 coronavirus
|
|
CA3166811A1
(en)
|
2020-02-13 |
2021-08-19 |
Nicolas Robert Xavier Escriou |
Measles-vectored covid-19 immunogenic compositions and vaccines
|
|
EP4103233A4
(en)
|
2020-02-14 |
2025-03-26 |
Epivax, Inc. |
T-CELL EPITOPES AND ASSOCIATED COMPOSITIONS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF COVID-19
|
|
GB2594683A
(en)
|
2020-02-17 |
2021-11-10 |
Vaxbio Ltd |
Vaccine
|
|
CN111303254A
(zh)
|
2020-02-20 |
2020-06-19 |
北京新创生物工程有限公司 |
新型冠状病毒（SARS-CoV-2）抗原检测试剂盒
|
|
WO2021000968A2
(zh)
|
2020-02-23 |
2021-01-07 |
广州恩宝生物医药科技有限公司 |
一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
|
|
CN110974950B
(zh)
|
2020-03-05 |
2020-08-07 |
广州恩宝生物医药科技有限公司 |
一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
|
|
CN110951756B
(zh)
|
2020-02-23 |
2020-08-04 |
广州恩宝生物医药科技有限公司 |
表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
|
|
CN112300251B
(zh)
|
2020-02-24 |
2022-04-05 |
成都威斯克生物医药有限公司 |
抗SARS-CoV-2感染的蛋白及疫苗
|
|
CN111218458B
(zh)
|
2020-02-27 |
2020-11-20 |
珠海丽凡达生物技术有限公司 |
编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
|
|
WO2021178306A1
(en)
|
2020-03-01 |
2021-09-10 |
Dynavax Technologies Corporation |
Coronavirus vaccines comprising a tlr9 agonist
|
|
US12269846B2
(en)
|
2020-03-05 |
2025-04-08 |
Swey-Shen Chen |
CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution
|
|
US20230346916A1
(en)
|
2020-03-05 |
2023-11-02 |
New York Blood Center, Inc. |
Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
|
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
|
WO2021183563A1
(en)
|
2020-03-09 |
2021-09-16 |
Arcturus Therapeutics, Inc. |
Coronavirus vaccine compositions and methods
|
|
US12285480B2
(en)
|
2020-03-11 |
2025-04-29 |
Nantcell, Inc. |
Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
|
|
CR20220501A
(es)
|
2020-03-13 |
2023-01-23 |
Oxford Univ Innovation Limite |
Composiciones y métodos para la inducción de una respuesta inmune
|
|
CN111218459B
(zh)
|
2020-03-18 |
2020-09-11 |
中国人民解放军军事科学院军事医学研究院 |
一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
|
|
US20230136960A1
(en)
|
2020-03-19 |
2023-05-04 |
Nature's Toolbox, Inc. |
Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same
|
|
IL296617A
(en)
|
2020-03-20 |
2022-11-01 |
Biontech Us Inc |
Vaccines against the corona virus and methods of use
|
|
CN111088283B
(zh)
|
2020-03-20 |
2020-06-23 |
苏州奥特铭医药科技有限公司 |
mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
|
|
CN111560074B
(zh)
|
2020-03-20 |
2021-07-09 |
中山大学 |
一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
|
|
US20230167159A1
(en)
|
2020-03-20 |
2023-06-01 |
Kansas State University Research Foundation |
Sars-coronavirus 2 (sars-cov-2) subunit vaccine candidates
|
|
US20240210415A1
(en)
|
2020-03-24 |
2024-06-27 |
Icahn School Of Medicine At Mount Sinai |
Recombinant sars-cov-2 spike protein and uses thereof
|
|
GB202004493D0
(en)
|
2020-03-27 |
2020-05-13 |
Imp College Innovations Ltd |
Coronavirus vaccine
|
|
JPWO2021200800A1
(https=)
|
2020-03-30 |
2021-10-07 |
|
|
|
US11559577B2
(en)
|
2020-03-31 |
2023-01-24 |
Engimata, Inc. |
Immunogenic composition forming a vaccine, and a method for its manufacture
|
|
WO2021201612A1
(ko)
|
2020-03-31 |
2021-10-07 |
주식회사 에스엘백시젠 |
신규 코로나바이러스 예방 및 치료용 백신 조성물
|
|
US11278617B2
(en)
|
2020-03-31 |
2022-03-22 |
Engimata, Inc |
Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
|
|
WO2021202599A2
(en)
|
2020-04-01 |
2021-10-07 |
Valiant Biosciences, Llc |
Adeno-associated virus based compositions and related methods for inducing humoral immunity
|
|
CA3174187A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Florida Research Foundation, Incorporated |
Multilamellar rna nanoparticle vaccine against sars-cov-2
|
|
US20240285751A1
(en)
|
2020-04-01 |
2024-08-29 |
Diosynvax Ltd |
Coronavirus vaccines
|
|
TW202202169A
(zh)
|
2020-04-02 |
2022-01-16 |
中央研究院 |
預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法
|
|
US20230158137A1
(en)
|
2020-04-03 |
2023-05-25 |
Peptc Vaccines Limited |
Coronavirus vaccine
|
|
CN111748557B
(zh)
|
2020-04-03 |
2022-03-11 |
苏州吉玛基因股份有限公司 |
抑制新型冠状病毒的小干扰核酸及组合物和应用
|
|
WO2021203044A2
(en)
|
2020-04-03 |
2021-10-07 |
Icahn School Of Medicine At Mount Sinai |
High-throughput assay for circulating antibodies against severe acute respiratory syndrome coronavirus 2
|
|
GB202004974D0
(en)
|
2020-04-03 |
2020-05-20 |
Treos Bio Ltd |
Coronavirus vaccine
|
|
RU2747762C1
(ru)
|
2020-04-05 |
2021-05-13 |
Илья Владимирович Духовлинов |
Вакцина для профилактики или лечения коронавирусной инфекции на основе генетической конструкции
|
|
CN112023035A
(zh)
|
2020-04-07 |
2020-12-04 |
中国医学科学院医学生物学研究所 |
一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
|
|
WO2021205455A1
(en)
|
2020-04-07 |
2021-10-14 |
Ramot At Tel-Aviv University Ltd. |
Sars-cov2 coronavirus reconstituted rbm and uses thereof
|
|
EP4132576A1
(en)
|
2020-04-09 |
2023-02-15 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
US20230310582A1
(en)
|
2020-04-14 |
2023-10-05 |
Duke University |
Sars-2 spike protein designs, compositions and methods for their use
|
|
WO2021211749A1
(en)
|
2020-04-14 |
2021-10-21 |
The Regents Of The University Of California |
Multi-epitope pan-coronavirus vaccine compositions
|
|
US12280102B2
(en)
|
2020-04-17 |
2025-04-22 |
Vlp Therapeutics, Inc. |
Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
|
|
WO2021209824A1
(en)
|
2020-04-17 |
2021-10-21 |
Institut Pasteur |
Methods and products for serological analysis of sars-cov-2 infection
|
|
EP4136095A1
(en)
|
2020-04-17 |
2023-02-22 |
Regents of the University of Minnesota |
Sars-cov-2 spike receptor binding domain and compositions and methods thereof
|
|
EP4138895A2
(en)
|
2020-04-20 |
2023-03-01 |
NEC OncoImmunity AS |
Sars-cov-2 vaccines
|
|
EP4138893A4
(en)
|
2020-04-21 |
2024-06-12 |
Intima Bioscience, Inc. |
CELLULAR VACCINE PLATFORM AND METHODS OF USE THEREOF
|
|
WO2021216738A2
(en)
|
2020-04-21 |
2021-10-28 |
Intima Bioscience, Inc. |
Compositions and methods of generating an immune response
|
|
WO2021212568A1
(zh)
|
2020-04-21 |
2021-10-28 |
苏州方科生物科技有限公司 |
新型冠状病毒特异性抗原肽及其用途
|
|
WO2021216743A2
(en)
|
2020-04-21 |
2021-10-28 |
Emory University |
Coronavirus vaccines, compositions, and methods related thereto
|
|
EP3901261A1
(en)
|
2020-04-22 |
2021-10-27 |
BioNTech RNA Pharmaceuticals GmbH |
Coronavirus vaccine
|
|
IL297414A
(en)
|
2020-04-22 |
2022-12-01 |
Pfizer |
Vaccine against the corona virus
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
KR102482994B1
(ko)
|
2020-04-29 |
2022-12-29 |
에스케이바이오사이언스(주) |
사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
|
|
IT202000009625A1
(it)
|
2020-04-30 |
2021-10-30 |
Takis S R L |
Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.
|
|
WO2021223647A1
(en)
|
2020-05-06 |
2021-11-11 |
The University Of Hong Kong |
Compositions and methods for making and using vaccines against covid-19
|
|
WO2021224946A1
(en)
|
2020-05-07 |
2021-11-11 |
Bharat Biotech International Limited |
Coronavirus vaccine through nasal immunization
|
|
CA3177940A1
(en)
|
2020-05-07 |
2021-11-11 |
Anusha DIAS |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
CN112695057B
(zh)
|
2020-05-11 |
2022-04-26 |
广东珩达生物医药科技有限公司 |
Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
|
|
EP4105228A4
(en)
|
2020-05-11 |
2023-10-11 |
Hengda Biomedical Technology Co., Ltd. |
SARS-COV-2 ANTIGEN POLYPEPTIDE, RECOMBINANT ADENO-ASSOCIATED VIRUS THEREOF AND APPLICATION IN THE PRODUCTION OF A VACCINE
|
|
JP2023525552A
(ja)
|
2020-05-12 |
2023-06-16 |
グレフェックス， インコーポレイテッド |
ワクチン抗原としてのコロナウイルススパイクタンパク質の操作、その設計及び使用
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
US20230181481A1
(en)
|
2020-05-15 |
2023-06-15 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating covid-19
|
|
US12331078B2
(en)
|
2020-05-18 |
2025-06-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same
|
|
CN111363858B
(zh)
|
2020-05-26 |
2020-09-29 |
南京黎明生物制品有限公司 |
2019-nCoV S基因检测核酸组合物及试剂盒与生产方法
|
|
MX2022015132A
(es)
|
2020-05-29 |
2023-03-08 |
CureVac SE |
Vacunas combinadas a base de acidos nucleicos.
|
|
WO2021253172A1
(zh)
|
2020-06-15 |
2021-12-23 |
上海市公共卫生临床中心 |
利用受体识别域诱导抗新冠病毒中和抗体的方法
|
|
US10906944B2
(en)
|
2020-06-29 |
2021-02-02 |
The Scripps Research Institute |
Stabilized coronavirus spike (S) protein immunogens and related vaccines
|
|
WO2022003119A1
(en)
|
2020-07-01 |
2022-01-06 |
CEBINA GmbH |
Cross-reactive coronavirus vaccine
|
|
WO2022000845A1
(zh)
|
2020-07-01 |
2022-01-06 |
江苏省疾病预防控制中心(江苏省公共卫生研究院) |
一种预防SARS-CoV-2的重组蛋白疫苗及其制备方法
|
|
WO2022006565A1
(en)
|
2020-07-03 |
2022-01-06 |
Kang Zhang |
Polypeptides, vaccine compositions, and use thereof for inducing immune response to sars-cov-2 in primates
|
|
GB2596820A
(en)
|
2020-07-07 |
2022-01-12 |
Spicona Inc |
Combination vaccine
|
|
US20230248818A1
(en)
|
2020-07-08 |
2023-08-10 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2
|
|
CN111978377B
(zh)
|
2020-07-09 |
2022-05-31 |
苏州和锐生物科技有限公司 |
Covid-19抗原、制备方法和应用
|
|
WO2022011332A2
(en)
|
2020-07-10 |
2022-01-13 |
Engimata, Inc |
Immunogenic composition forming a vaccine, and a method for its manufacture
|
|
CN112043825B
(zh)
|
2020-07-13 |
2023-12-05 |
中国医学科学院医学生物学研究所 |
一种基于新型冠状病毒突刺蛋白s1区域预防新型冠状病毒感染的亚单位疫苗
|
|
CN111848753B
(zh)
|
2020-07-20 |
2022-03-15 |
中国科学院过程工程研究所 |
新型冠状病毒抗原表位及其应用
|
|
RU2733834C1
(ru)
|
2020-07-28 |
2020-10-07 |
Федеральное бюджетное учреждение науки Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) |
Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
|
|
CN112028976A
(zh)
|
2020-08-05 |
2020-12-04 |
上海裕隆生物科技有限公司 |
2019新型冠状病毒刺突蛋白受体结合结构域蛋白及应用
|
|
CN111939250B
(zh)
|
2020-08-17 |
2022-07-29 |
郑州大学 |
一种预防covid-19的疫苗及其制备方法
|
|
RU2731342C9
(ru)
|
2020-08-22 |
2021-10-05 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
|
|
RU2731356C9
(ru)
|
2020-08-22 |
2021-10-05 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
|
|
CN112048005B
(zh)
|
2020-09-04 |
2022-09-09 |
江苏省中国科学院植物研究所 |
新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物
|
|
CN112094327A
(zh)
|
2020-09-25 |
2020-12-18 |
军事科学院军事医学研究院军事兽医研究所 |
基于新型冠状病毒rbd-sd1蛋白的截短体及其应用
|
|
CN112266411B
(zh)
|
2020-09-25 |
2022-06-24 |
北京诺思兰德生物技术股份有限公司 |
一种新型冠状病毒疫苗及其应用
|
|
CN112226445B
(zh)
|
2020-10-20 |
2021-05-11 |
成都欧林生物科技股份有限公司 |
编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用
|
|
US20230416309A1
(en)
|
2020-10-23 |
2023-12-28 |
Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji |
Fusion protein and application thereof
|
|
CN112358533B
(zh)
|
2020-10-30 |
2023-07-14 |
上海泽润生物科技有限公司 |
重组刺突蛋白及其制备方法和用途
|
|
CN112220920B
(zh)
|
2020-10-30 |
2023-06-13 |
上海泽润生物科技有限公司 |
一种重组新型冠状病毒疫苗组合物
|
|
US20240041785A1
(en)
|
2020-11-16 |
2024-02-08 |
BioNTech SE |
Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
|
|
CN114517205A
(zh)
|
2020-11-20 |
2022-05-20 |
北京震旦鼎泰生物科技有限公司 |
融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用
|
|
CN112480217B
(zh)
|
2020-11-30 |
2022-04-08 |
广州阿格纳生物医药制造有限公司 |
基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
|
|
CN112626089B
(zh)
|
2020-12-08 |
2022-03-11 |
杭州百凌生物科技有限公司 |
一种SARS-CoV-2病毒S蛋白受体结合区域编码基因、抗体及应用
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
CN112794884B
(zh)
|
2020-12-28 |
2022-02-18 |
中国科学院微生物研究所 |
新型冠状病毒蛋白、制备方法及中和抗体检测试剂盒
|
|
CN112321688B
(zh)
|
2021-01-06 |
2021-03-26 |
广东华南疫苗股份有限公司 |
稳定的冠状病毒重组蛋白二聚体及其表达载体
|
|
EP4308156A1
(en)
|
2021-03-15 |
2024-01-24 |
ModernaTX, Inc. |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
CN116003496A
(zh)
*
|
2021-11-24 |
2023-04-25 |
南京吉迈生物技术有限公司 |
经修饰的mRNA5`-帽类似物
|